A randomized controlled study of Yiqi Fumai injection in the treatment of heart failure with preserved ejection fraction

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2025001150

Enrollment

Unknown

Registered

2025-06-12

Start date

2025-02-20

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with preserved ejection fraction

Interventions

control group:western medicine treatment for heart failure

test group:Yiqi Fumai injection

Eligibility

Sex/Gender

All

Age

35 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1: people were selected with certain diagnostic standard. 2: New York College of Cardiology (NYHA) Heart Function Grade II to III 3: Over 35 years old 4: Consent to treatment and sign an informed consent form 5: No recent participation in other clinical trials

Exclusion criteria

Exclusion criteria: 1: Complicated with severe liver and kidney failure respiratory failure infection trauma and tumor disease 2: Patients during lactation or pregnancy 3: Patients with mental illness cognitive impairment 4: Allergic to the investigational drug

Design outcomes

Primary

Measure	Time frame
6MWT;	—

Secondary

Measure	Time frame
NT-RPOBNP;Heart function grade of NYHA;heart echocardiography monitoring;resting cardiac output;	—

Countries

China

Contacts

Public ContactXu Danping

The Eighth Affiliated Hospital of Sun Yat-sen University

xudp3@mail.sysu.edu.cn+86 755 8398 2222

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026